Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a salad ingredient help treat diabetes? new trial underway

NCT ID NCT07546929

Disease control Sponsor: Housey Healthcare ULC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests HP-211, a botanical extract from common vegetables like endive and lettuce, in 300 people with type 2 diabetes. The goal is to see if it can improve how the body uses insulin and lower blood sugar levels over 90 days. Participants take HP-211 or a placebo twice daily, and researchers measure changes in HbA1c, a key blood sugar marker.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HP-211 (a botanical extract from endive, lettuce, and tarragon)
What this could lead to
If it works, HP-211 could offer a new, natural option to help control blood sugar and reduce insulin resistance in type 2 diabetes, potentially preventing or delaying complications.
What could go wrong
This is an early Phase 2 study with only 300 people, so results may not apply to everyone. The extract is new, and its long-term safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Have type 2 diabetes for greater than 3 months and no longer than 5 years by history prior to entering the trial, based upon ADA disease diagnostic criteria. * Have an HbA1c \> 6.5% and ≤ 10% as determined by the central lab at Visit 1 (Screening). * Have been on a stable maximum dose of metformin for at least 3 months prior to entering the study or have been on stable therapy of diet and exercise only for at least 3 months. Stable treatment is defined as no change in treatment or dose in the last 3 months. Key Exclusion Criteria: * Have known type 1 diabetes. * Diabetic complications * Have taken any oral (other than metformin) or injectable treatment (insulin or GLP-1 RA classes or other) for type 2 diabetes currently or for greater than a 4 week duration previously. Previous treatment must have been stopped at least 3 months prior to screening * Systolic blood pressure greater than 150 mmHg or a diastolic blood pressure greater than 100 mmHg at Visit 1 on average after three supine measurements, or a known history of renal artery stenosis. * At baseline, the QT interval corrected by Fridericia (QTcF) ECG findings (\>450 msec for males and \>470 msec for females), left bundle branch block, or cardiac arrhythmia requiring medical or surgical treatment within 6 months prior to Visit 1 on the ECG.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    25 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AMR Clinical - El Dorado

    RECRUITING

    El Dorado, Kansas, 67042, United States

  • Advanced Medical Research

    RECRUITING

    Maumee, Ohio, 43537, United States

    Contact Email: •••••@•••••

  • Alliance Clinical Canoga Park (Hope Clinical Research)

    RECRUITING

    Canoga Park, California, 91303, United States

  • Alliance Clinical Las Vegas (Excel Clinical Research)

    RECRUITING

    Las Vegas, Nevada, 89109, United States

  • Alliance Clinical Lewisville (Epic Clinical Research)

    RECRUITING

    Lewisville, Texas, 75057, United States

    Contact Email: •••••@•••••

  • Arcturus Healthcare, PLC, Troy Internal Medicine Research Division

    RECRUITING

    Troy, Michigan, 48098, United States

  • Avantis Clinical Research

    RECRUITING

    Miami, Florida, 33155, United States

    Contact Email: •••••@•••••

  • Burke Internal Medicine & Research

    RECRUITING

    Burke, Virginia, 22015, United States

  • David Kavtaradze MD InC

    RECRUITING

    Cordele, Georgia, 31015, United States

  • Diabetes & Endocrinology Associates of Stark County, Inc.

    RECRUITING

    Canton, Ohio, 44718, United States

  • IMIC Research

    RECRUITING

    Miami, Florida, 33176, United States

  • Simcare Medical Research, LLC.

    RECRUITING

    Sugar Land, Texas, 77478, United States

    Contact Email: •••••@•••••

  • South Broward Research

    RECRUITING

    Miramar, Florida, 33027, United States

    Contact Email: •••••@•••••

  • Southwest General Healthcare Center

    RECRUITING

    Fort Myers, Florida, 33907, United States

    Contact Email: •••••@•••••

  • Tandem Clinical Research (Interspond)

    RECRUITING

    Marrero, Louisiana, 70072, United States

  • Tekton Research

    RECRUITING

    Irving, Texas, 75039, United States

    Contact Email: •••••@•••••

  • Tekton Research

    RECRUITING

    McKinney, Texas, 75069, United States

    Contact Email: •••••@•••••

  • Tekton Research

    RECRUITING

    San Antonio, Texas, 78258, United States

    Contact Email: •••••@•••••

  • Tekton Research

    RECRUITING

    Midlothian, Virginia, 23112, United States

  • Universal Axon Clinical Research

    RECRUITING

    Doral, Florida, 33166, United States

    Contact Email: •••••@•••••

  • Velocity Clinical Research Dallas

    RECRUITING

    Dallas, Texas, 75230, United States

  • Velocity Clinical Research New Smyrna Beach

    RECRUITING

    Edgewater, Florida, 32132, United States

  • Velocity Clinical Research Norfolk

    RECRUITING

    Norfolk, Nebraska, 68701, United States

    Contact Email: •••••@•••••

  • Velocity Clinical Research Providence

    RECRUITING

    East Greenwich, Rhode Island, 02818, United States

  • Velocity Clinical Research Waco

    RECRUITING

    Waco, Texas, 76710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.